PE20141189A1 - Preparacion de liberacion sostenida - Google Patents
Preparacion de liberacion sostenidaInfo
- Publication number
- PE20141189A1 PE20141189A1 PE2014000558A PE2014000558A PE20141189A1 PE 20141189 A1 PE20141189 A1 PE 20141189A1 PE 2014000558 A PE2014000558 A PE 2014000558A PE 2014000558 A PE2014000558 A PE 2014000558A PE 20141189 A1 PE20141189 A1 PE 20141189A1
- Authority
- PE
- Peru
- Prior art keywords
- sustained release
- release preparation
- pioglitazone
- gel
- water
- Prior art date
Links
- 239000003405 delayed action preparation Substances 0.000 title abstract 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 4
- 239000013078 crystal Substances 0.000 abstract 2
- 229960005095 pioglitazone Drugs 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000008107 starch Substances 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011232302 | 2011-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141189A1 true PE20141189A1 (es) | 2014-09-24 |
Family
ID=47178262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014000558A PE20141189A1 (es) | 2011-10-21 | 2012-10-19 | Preparacion de liberacion sostenida |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9907789B2 (enExample) |
| EP (1) | EP2768487B1 (enExample) |
| JP (1) | JP6093762B2 (enExample) |
| KR (1) | KR20140081826A (enExample) |
| CN (1) | CN104039313A (enExample) |
| AP (1) | AP2014007645A0 (enExample) |
| AR (1) | AR088398A1 (enExample) |
| AU (1) | AU2012326976B2 (enExample) |
| BR (1) | BR112014008744A2 (enExample) |
| CA (1) | CA2852417A1 (enExample) |
| CL (1) | CL2014000992A1 (enExample) |
| CO (1) | CO6960544A2 (enExample) |
| CR (1) | CR20140213A (enExample) |
| DO (1) | DOP2014000077A (enExample) |
| EA (1) | EA201490840A1 (enExample) |
| EC (1) | ECSP14013328A (enExample) |
| IL (1) | IL232114A0 (enExample) |
| IN (1) | IN2014DN03169A (enExample) |
| MA (1) | MA35717B1 (enExample) |
| MX (1) | MX2014004679A (enExample) |
| NZ (1) | NZ624275A (enExample) |
| PE (1) | PE20141189A1 (enExample) |
| PH (1) | PH12014500856A1 (enExample) |
| SG (2) | SG2014012025A (enExample) |
| TN (1) | TN2014000152A1 (enExample) |
| TW (1) | TW201323018A (enExample) |
| UA (1) | UA113858C2 (enExample) |
| UY (1) | UY34403A (enExample) |
| WO (1) | WO2013058409A1 (enExample) |
| ZA (1) | ZA201403103B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP2014007645A0 (en) | 2011-10-21 | 2014-05-31 | Takeda Pharmaceutical | Sustained-release preparation |
| ES2668422T3 (es) | 2012-04-20 | 2018-05-18 | Gilead Sciences, Inc. | Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH |
| US20150141517A1 (en) * | 2013-11-15 | 2015-05-21 | Shin-Etsu Chemical Co., Ltd. | Granulated composite, rapid release tablet and method for producing same |
| KR102485766B1 (ko) | 2019-12-11 | 2023-01-09 | 한국유나이티드제약 주식회사 | 생체이용률이 향상된 피오글리타존 함유 약학조성물 |
| UY39094A (es) * | 2020-02-27 | 2021-07-30 | Hk Inno N Corp | Composición farmacéutica que comprende compuesto derivado de bencimidazol |
| JP2023066053A (ja) * | 2021-10-28 | 2023-05-15 | 東和薬品株式会社 | 放出制御医薬組成物 |
| WO2025064867A1 (en) * | 2023-09-21 | 2025-03-27 | Yuva Biosciences, Inc. | Delivery system for mitochondrial health enhancers |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810502A (en) | 1987-02-27 | 1989-03-07 | Alza Corporation | Pseudoephedrine brompheniramine therapy |
| US4820522A (en) | 1987-07-27 | 1989-04-11 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| JPH0624991A (ja) | 1991-06-20 | 1994-02-01 | Tokyo Tanabe Co Ltd | ウルソデスオキシコール酸持続性製剤 |
| JPH0624959A (ja) | 1991-10-04 | 1994-02-01 | Bayer Yakuhin Kk | 胃内浮遊型薬物徐放性固形製剤 |
| DE69332081T2 (de) | 1992-09-18 | 2003-02-06 | Yamanouchi Pharmaceutical Co., Ltd. | Hydrogelzubereitung mit verzögerter freisetzung |
| JPH06316517A (ja) | 1993-02-22 | 1994-11-15 | Grelan Pharmaceut Co Ltd | 放出制御製剤 |
| WO1998056359A2 (de) | 1997-06-13 | 1998-12-17 | Roland Bodmeier | Zusammensetzungen, die die wirkstofffreisetzung verzögern |
| US6191154B1 (en) | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
| WO2003013609A1 (fr) | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Medicaments a liberation continue |
| KR20100137023A (ko) | 2002-09-20 | 2010-12-29 | 안드렉스 랩스 엘엘씨 | 약제학적 정제 |
| US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| JP4493970B2 (ja) | 2002-10-16 | 2010-06-30 | 武田薬品工業株式会社 | 持続性製剤 |
| IN192749B (enExample) | 2002-11-15 | 2004-05-15 | Ranbaxy Lab Ltd | |
| US7442387B2 (en) | 2003-03-06 | 2008-10-28 | Astellas Pharma Inc. | Pharmaceutical composition for controlled release of active substances and manufacturing method thereof |
| EP1607088B1 (en) | 2003-03-17 | 2019-02-27 | Takeda Pharmaceutical Company Limited | Controlled release composition |
| JP4933033B2 (ja) | 2003-03-17 | 2012-05-16 | 武田薬品工業株式会社 | 放出制御組成物 |
| WO2004108161A1 (ja) | 2003-06-06 | 2004-12-16 | Takeda Pharmaceutical Company Limited | 固形製剤 |
| JP2005015477A (ja) | 2003-06-06 | 2005-01-20 | Takeda Chem Ind Ltd | 固形製剤 |
| US20060003002A1 (en) | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
| EP1738754B1 (en) | 2004-04-14 | 2015-07-15 | Takeda Pharmaceutical Company Limited | Solid pharmaceutical preparation |
| EP1789022A2 (en) | 2004-08-31 | 2007-05-30 | Pfizer Products Incorporated | Controlled release dosage forms combining immediate release and sustained release of low-solubility drug |
| KR20080058413A (ko) | 2005-09-22 | 2008-06-25 | 에스비 팜코 푸에르토 리코 인크. | Ａｐｏｅ4 음성 환자에서의 인지 기능의 개선을 위한ｐｐａｒ-감마 작동제 |
| WO2007054976A2 (en) | 2005-11-08 | 2007-05-18 | Panacea Biotec Ltd. | Lipid based controlled release pharmaceutical composition |
| KR20080080126A (ko) | 2005-12-22 | 2008-09-02 | 다케다 야쿠힌 고교 가부시키가이샤 | 인슐린 감작제를 함유하는 고체 제제 |
| PL2002828T3 (pl) | 2006-03-30 | 2019-11-29 | Nippon Zoki Pharmaceutical Co | Stały preparat farmaceutyczny |
| PE20080696A1 (es) | 2006-04-27 | 2008-08-04 | Takeda Pharmaceutical | Composicion farmaceutica solida que comprende un derivado de bencimidazol y clorhidrato de pioglitazona |
| AU2008213744B2 (en) | 2007-02-09 | 2013-12-05 | Alphapharm Pty Ltd | A dosage form containing two or more active pharmaceutical ingredients in different physical forms |
| TW200914006A (en) * | 2007-07-12 | 2009-04-01 | Takeda Pharmaceutical | Coated preparation |
| CN101269040A (zh) * | 2008-05-16 | 2008-09-24 | 北京正大绿洲医药科技有限公司 | 盐酸吡格列酮缓释滴丸及其制备方法 |
| AU2009298684B2 (en) | 2008-09-30 | 2015-11-19 | Konstantinos Ritis | Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors |
| TWI478712B (zh) * | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
| WO2011049309A2 (ko) | 2009-10-09 | 2011-04-28 | 영진약품공업 주식회사 | 속효성과 지속성을 동시에 갖는 약제학적 조성물 |
| JP2011232302A (ja) | 2010-04-30 | 2011-11-17 | Ricoh Elemex Corp | 画像検査方法及び画像検査装置 |
| CN101884627B (zh) | 2010-07-07 | 2012-01-25 | 青岛黄海制药有限责任公司 | 盐酸吡格列酮胃内滞留缓释片及其制备方法 |
| PH12013501450A1 (en) | 2011-01-10 | 2013-08-28 | Takeda Pharmaceuticals Co | Methods and drug products for treating alzheimer`s diseases |
| AP2014007645A0 (en) | 2011-10-21 | 2014-05-31 | Takeda Pharmaceutical | Sustained-release preparation |
| KR20160056691A (ko) | 2014-11-12 | 2016-05-20 | 삼성에스디아이 주식회사 | 이차전지 |
-
2012
- 2012-10-19 AP AP2014007645A patent/AP2014007645A0/xx unknown
- 2012-10-19 AR ARP120103908A patent/AR088398A1/es unknown
- 2012-10-19 IN IN3169DEN2014 patent/IN2014DN03169A/en unknown
- 2012-10-19 MX MX2014004679A patent/MX2014004679A/es unknown
- 2012-10-19 UY UY0001034403A patent/UY34403A/es not_active Application Discontinuation
- 2012-10-19 AU AU2012326976A patent/AU2012326976B2/en not_active Ceased
- 2012-10-19 UA UAA201405332A patent/UA113858C2/uk unknown
- 2012-10-19 JP JP2014518853A patent/JP6093762B2/ja not_active Expired - Fee Related
- 2012-10-19 EP EP12784752.3A patent/EP2768487B1/en active Active
- 2012-10-19 SG SG2014012025A patent/SG2014012025A/en unknown
- 2012-10-19 CN CN201280062591.4A patent/CN104039313A/zh active Pending
- 2012-10-19 PE PE2014000558A patent/PE20141189A1/es not_active Application Discontinuation
- 2012-10-19 TW TW101138592A patent/TW201323018A/zh unknown
- 2012-10-19 EA EA201490840A patent/EA201490840A1/ru unknown
- 2012-10-19 WO PCT/JP2012/077662 patent/WO2013058409A1/en not_active Ceased
- 2012-10-19 PH PH1/2014/500856A patent/PH12014500856A1/en unknown
- 2012-10-19 US US14/352,785 patent/US9907789B2/en active Active
- 2012-10-19 BR BR112014008744A patent/BR112014008744A2/pt not_active IP Right Cessation
- 2012-10-19 NZ NZ624275A patent/NZ624275A/en not_active IP Right Cessation
- 2012-10-19 KR KR1020147010504A patent/KR20140081826A/ko not_active Ceased
- 2012-10-19 CA CA2852417A patent/CA2852417A1/en not_active Abandoned
- 2012-10-19 SG SG10201700121YA patent/SG10201700121YA/en unknown
-
2014
- 2014-04-11 TN TNP2014000152A patent/TN2014000152A1/en unknown
- 2014-04-13 IL IL232114A patent/IL232114A0/en unknown
- 2014-04-15 DO DO2014000077A patent/DOP2014000077A/es unknown
- 2014-04-17 CL CL2014000992A patent/CL2014000992A1/es unknown
- 2014-04-29 EC ECSP14013328 patent/ECSP14013328A/es unknown
- 2014-04-29 ZA ZA2014/03103A patent/ZA201403103B/en unknown
- 2014-05-09 CR CR20140213A patent/CR20140213A/es unknown
- 2014-05-14 CO CO14103846A patent/CO6960544A2/es unknown
- 2014-05-15 MA MA37034A patent/MA35717B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20141189A1 (es) | Preparacion de liberacion sostenida | |
| PH12019500517A1 (en) | Long-acting formulations of insulins | |
| UA107112C2 (uk) | Активатори розчинної гуанілатциклази | |
| JP2010222367A5 (enExample) | ||
| AR081681A1 (es) | METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA | |
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| BR112015008954A2 (pt) | composições de ciclodextrina alquilatada e processos para preparação e uso das mesmas | |
| MX2021006021A (es) | Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos. | |
| PE20130379A1 (es) | Metodos para el tratamiento de las ulceras del pie diabetico | |
| CL2012003488A1 (es) | Formulación intravenosa que comprende una solución acuosa de sulfobutil-eter-beta-ciclodextrina y amiodarona o una sal en proporción entre 2,7: 1 a 7:1; metodo de preparación; un artículo manufacturado, util en arritmias. | |
| AR096854A1 (es) | Composición farmacéutica para una liberación sostenida de lanreotide | |
| CY1118036T1 (el) | Βελτιστοποιημενη συνθεση καθαρων μη-πολυμορφικων, κρυσταλλικων χολικων οξεων με καθορισμενο μεγεθος σωματιδιων | |
| MX349854B (es) | Composiciones antitranspirantes y metodo para reducir la transpiracion. | |
| MX349364B (es) | Variante de alfa-1 antitripsina novedosa, método de preparación de la misma, y uso de la misma. | |
| AR090244A1 (es) | Formulacion de anticuerpo anti-selectina p | |
| EA201390979A1 (ru) | Композиции бензимидазолов с модифицированным высвобождением | |
| PE20140962A1 (es) | Una formulacion farmaceutica solida | |
| TR200806300A2 (tr) | Çözünürlük artırıcı farmasötlk formulasyon | |
| BR112014016804A2 (pt) | composições, métodos de uso e métodos de tratamento | |
| ES2552521T3 (es) | Infusión intravenosa de ibuprofeno | |
| CY1122538T1 (el) | Συμπλεγματα χονδροϊτινης για διαδερμικη απορροφηση | |
| IN2014DN10134A (enExample) | ||
| EA201500446A1 (ru) | Фармацевтическая композиция для снижения уровня n-оксида триметиламина | |
| BR112015004115A2 (pt) | composições farmacêuticas compreendendo flurbiprofeno | |
| UA107155C2 (uk) | Стабільна композиція для лікування герпесвірусних інфекцій |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |